LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells

Molecular Cancer Research

Volumn 11, Issue 5, 2013, Pages 541-554

  Talab, Fatima ^a   Allen, John C ^a   Thompson, Victoria ^a   Lin, Ke ^b   Slupsky, Joseph R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD79A ANTIGEN; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE LCK; PROTEIN KINASE SYK; SMALL INTERFERING RNA;

ARTICLE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

B-LYMPHOCYTES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84877889513     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0415-T     Document Type: Article

References (59)

1. Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol 2008;81:253-8.
2. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008; 371:1017-29.
3. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118:4313-20.
4. Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J, et al. Multiple distinct sets of stereotyped antigen aeceptors andicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200:519-25.
5. Ghiotto F, Fais F, Valetto A, Albesiano E, Hashimoto S, Dono M, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004;113:1008-16.
6. Hervé M, Xu K, Ng YS, Wardemann H, Albesiano E, Messmer BT, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005;115:1636-43.
7. Krysov S, Potter KN, Mockridge CI, Coelho V, Wheatley I, Packham G, et al. Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. Blood 2010;115:4198-205.
8. κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-74.
9. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119:1182-9.
10. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85.
11. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3d-kinase delta inhibitor, CAL- 101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603-12.
12. Efremov DG, Gobessi S, Longo PG. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia Bcells. Autoimmun Rev 2007;7:102-8.
13. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115:369-78.
14. Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholomé K, Burger M, et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009;69:5424-32.
15. Veldurthy A, Patz M, Hagist S, Pallasch CP, Wendtner CM, Hallek M, et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008;112:1443-52.
16. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variableregion mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
17. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105.
18. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-51.
19. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP- 70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007;109:2032-9.
20. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008;111:2685-92.
21. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994;76:263-74.
22. Majolini MB, D'Elios MM, Galieni P, Boncristiano M, Lauria F, Del Prete G, et al. Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cells. Blood 1998; 91:3390-6.
23. Dal Porto JM, Burke K, Cambier JC. Regulation of BCR signal transduction in B-1 cells requires the expression of the Src family kinase Lck. Immunity 2004;21:443-53.
24. -/- mice. Eur J Immunol 2003;33:441-5.
25. Huber S, Oelsner M, Decker T, zum Büschenfelde CM, Wagner M, Lutzny G, et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011; 25:838-47.
26. Paterson JC, Tedoldi S, Craxton A, Jones M, Hansmann ML, Collins G, et al. The differential expression of LCK and BAFF-receptor and their role inapoptosis inhuman lymphomas. Haematologica 2006;91:772-80.
27. Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, et al. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ 2010;17:1381-91.
28. Lin K, Glenn MA, Harris RJ, Duckworth AD, Dennett S, Cawley JC, et al. c-Abl expression in CLL cells: clinical and therapeutic implications. Cancer Res 2006;66:7801-9.
29. Abrams ST, Lakum T, Lin K, Jones GM, Treweeke AT, Farahani M, et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbII. Blood 2007;109:1193-201.
30. Young RM, Holowka D, Baird B. A lipid raft environment enhances Lyn kinase activity by protecting the active site tyrosine from dephosphorylation. J Biol Chem 2003;278:20746-52.
31. Allen JC, Talab F, Zuzel M, Lin K, Slupsky JR. c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells. Blood 2011;117:2414-22.
32. Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev 2009; 228:9-22.
33. Arnold LD, Calderwood DJ, Dixon RW, Johnston DN, Kamens JS, Munschauer R, et al. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett 2000;10:2167-70.
34. Burchat AF, Calderwood DJ, Hirst GC, Holman NJ, Johnston DN, Munschauer R, et al. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II. Bioorg Med Chem Lett 2000;10:2171-4.
35. Calderwood DJ, Johnston DN, Munschauer R, Rafferty P. Pyrrolo[2,3- d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck. Bioorg Med Chem Lett 2002;12:1683-6.
36. Williams NK, Lucet IS, Klinken SP, Ingley E, Rossjohn J. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state. J Biol Chem 2009;284:284-91.
37. Kesavan KP, Isaacson CC, Ashendel CL, Geahlen RL, Harrison ML. Characterization of the in vivo sites of serine phosphorylation on Lck identifying serine 59 as a site of mitotic phosphorylation. J Biol Chem 2002;277:14666-73.
38. Winkler DG, Park I, Kim T, Payne NS, Walsh CT, Strominger JL, et al. Phosphorylation of Ser-42 and Ser-59 in the N-terminal region of the tyrosine kinase p56lck. Proc Natl Acad Sci U S A 1993;90:5176-80.
39. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leukemia Res 1999;23:127-36.
40. Gong Q, Jin X, Akk AM, Foger N, White M, Gong G, et al. Requirement for tyrosine residues 315 and 319 within χ chain-associated Protein 70 for T cell development. J Exp Med 2001;194:507-18.
41. Saijo K, Mecklenbrauker I, Santana A, Leitger M, Schmedt C, Tarakhovsky A. Protein kinase Cβ controls nuclear factor κBactivation in B cells through selective regulation of the IκB kinaseα. J Exp Med 2002;195:1647-52.
42. Shinohara H, Yasuda T, Aiba Y, Sanjo H, Hamadate M, Watarai H, et al. PKCβ regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med 2005;202: 1423-31.
43. 2+ mobilization through distinct pathways. EMBO J 1994;13:1341-9.
44. Costello PS, Walters AE, Mee PJ, Turner M, Reynolds LF, Prisco A, et al. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-κB pathways. Proc Natl Acad Sci U S A 1999;96:3035-40.
45. Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS, et al. Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood 2012;119:1726-36.
46. Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005;105:4820-7.
47. Allsup DJ, Kamiguti AS, Lin K, Sherrington PD, Matrai Z, Slupsky JR, et al. B-Cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res 2005;65:7328-37.
48. Ochi H, Watanabe T. Negative regulation of B cell receptor-mediated signaling in B-1 cells through CD5 and Ly49 co-receptors via Lyn kinase activity. Int Immunol 2000;12:1417-23.
49. Tibaldi E, Brunati AM, Zonta F, Frezzato F, Gattazzo C, Zambello R, et al. Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia 2011;25:1768-81.
50. Gary-Gouy H, Lang V, Sarun S, Boumsell L, Bismuth G. In vivo association of CD5 with tyrosine-phosphorylated ZAP-70 and p21 phospho-zeta molecules in human CD3+ thymocytes. J Immunol 1997;159:3739-47.
51. Arechiga AF, Habib T, He Y, Zhang X, Zhang ZY, Funk A, et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 2009;182:3343-7.
52. O'Neill SK, Getahun A, Gauld SB, Merrell KT, Tamir I, Smith MJ, et al. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. Immunity 2011;35:746-56.
53. Nika K, Soldani C, Salek M, Paster W, Gray A, Etzensperger R, et al. Constitutively active Lck kinase in T cells drives antigen receptor signal transduction. Immunity 2010;32:766-77.
54. Pelosi M, Di Bartolo V, Mounier V, Mège D, Pascussi JM, Dufour E, et al. Tyrosine 319 in the interdomain B of ZAP-70 is a binding site for the Src homology 2 domain of Lck. J Biol Chem 1999;274: 14229-37.
55. Gelkop S, Gish GD, Babichev Y, Pawson T, Isakov N. T cell activationinduced CrkII binding to the Zap70 protein tyrosine kinase is mediated by Lck-dependent phosphorylation of Zap70 tyrosine 315. J Immunol 2005;175:8123-32.
56. Couture C, Baier G, Altman A, Mustelin T. p56lck-independent activation and tyrosine phosphorylation of p72syk by T-cell antigen receptor/CD3 stimulation. Proc Natl Acad Sci U S A 1994;91: 5301-5.
57. Couture C, Deckert M, Williams S, Russo FO, Altman A, Mustelin T. Identification of the site in the syk protein tyrosine kinase that binds the SH2 domain of Lck. J Biol Chem 1996;271:24294-9.
58. Carsetti L, Laurenti L, Gobessi S, Longo PG, Leone G, Efremov DG. Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation. Cell Signal 2009;21:1187-94.
59. Martin MW, Machacek MR. Update on lymphocyte specific kinase inhibitors: a patent survey. Expert Opin Ther Pat 2010;20:1573-93.